Byrd JC - Search Results

1

Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.

Munir T, Brown JR, O'Brien S, Barrientos JC, Barr PM, Reddy NM, Coutre S, Tam CS, Mulligan SP, Jaeger U, Kipps TJ, Moreno C, Montillo M, Burger JA, Byrd JC, Hillmen P, Dai S, Szoke A, Dean JP, Woyach JA. Munir T, et al. Among authors: byrd jc. Am J Hematol. 2019 Dec;94(12):1353-1363. doi: 10.1002/ajh.25638. Epub 2019 Oct 13. Am J Hematol. 2019. PMID: 31512258 Free PMC article. Clinical Trial.

2

Advances in the therapy of chronic lymphocytic leukemia.

Johnson AJ, Mone AP, Abhyankar V, Byrd JC. Johnson AJ, et al. Among authors: byrd jc. Curr Opin Hematol. 2003 Jul;10(4):297-305. doi: 10.1097/00062752-200307000-00008. Curr Opin Hematol. 2003. PMID: 12799536 Review.

3

Rituximab in B-cell chronic lymphocytic leukemia.

Lin TS, Lucas MS, Byrd JC. Lin TS, et al. Among authors: byrd jc. Semin Oncol. 2003 Aug;30(4):483-92. doi: 10.1016/s0093-7754(03)00239-2. Semin Oncol. 2003. PMID: 12939717 Review.

4

Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

Lozanski G, Heerema NA, Flinn IW, Smith L, Harbison J, Webb J, Moran M, Lucas M, Lin T, Hackbarth ML, Proffitt JH, Lucas D, Grever MR, Byrd JC. Lozanski G, et al. Among authors: byrd jc. Blood. 2004 May 1;103(9):3278-81. doi: 10.1182/blood-2003-10-3729. Epub 2004 Jan 15. Blood. 2004. PMID: 14726385 Free article.

5

Management guidelines for use of alemtuzumab in B-cell chronic lymphocytic leukemia.

Keating M, Coutré S, Rai K, Osterborg A, Faderl S, Kennedy B, Kipps T, Bodey G, Byrd JC, Rosen S, Dearden C, Dyer MJ, Hillmen P. Keating M, et al. Among authors: byrd jc. Clin Lymphoma. 2004 Mar;4(4):220-7. doi: 10.3816/clm.2004.n.002. Clin Lymphoma. 2004. PMID: 15072613

6

FCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemia.

Lin TS, Flinn IW, Modali R, Lehman TA, Webb J, Waymer S, Moran ME, Lucas MS, Farag SS, Byrd JC. Lin TS, et al. Among authors: byrd jc. Blood. 2005 Jan 1;105(1):289-91. doi: 10.1182/blood-2004-02-0651. Epub 2004 Jun 24. Blood. 2005. PMID: 15217834 Free article. Clinical Trial.

7

Antibody therapy for chronic lymphocytic leukemia: a promising new modality.

Lin TS, Moran M, Lucas M, Waymer S, Jefferson S, Fischer DB, Grever MR, Byrd JC. Lin TS, et al. Among authors: byrd jc. Hematol Oncol Clin North Am. 2004 Aug;18(4):895-913, ix-x. doi: 10.1016/j.hoc.2004.04.008. Hematol Oncol Clin North Am. 2004. PMID: 15325705 Review.

8

ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Rassenti LZ, Huynh L, Toy TL, Chen L, Keating MJ, Gribben JG, Neuberg DS, Flinn IW, Rai KR, Byrd JC, Kay NE, Greaves A, Weiss A, Kipps TJ. Rassenti LZ, et al. Among authors: byrd jc. N Engl J Med. 2004 Aug 26;351(9):893-901. doi: 10.1056/NEJMoa040857. N Engl J Med. 2004. PMID: 15329427 Free article.

9

Chronic lymphocytic leukemia.

Byrd JC, Stilgenbauer S, Flinn IW. Byrd JC, et al. Hematology Am Soc Hematol Educ Program. 2004:163-83. doi: 10.1182/asheducation-2004.1.163. Hematology Am Soc Hematol Educ Program. 2004. PMID: 15561682 Review.

10

TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia.

Raval A, Lucas DM, Matkovic JJ, Bennett KL, Liyanarachchi S, Young DC, Rassenti L, Kipps TJ, Grever MR, Byrd JC, Plass C. Raval A, et al. Among authors: byrd jc. J Clin Oncol. 2005 Jun 10;23(17):3877-85. doi: 10.1200/JCO.2005.02.196. Epub 2005 Apr 4. J Clin Oncol. 2005. PMID: 15809452

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

846 results

Search Page